TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00683514
Drug: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4
Study: NCT00683514
Drug: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1
Study: NCT00262769
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
Study: NCT00262769
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
Study: NCT01536535
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
Study: NCT00948103
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
Study: NCT00948103
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxygen
Study: NCT03456843
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Study: NCT00094497
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00094497
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00094497
Drug: Streptozotocin
Normalized name: Streptozotocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00094497
Drug: Mitotane
Normalized name: Mitotane
DrugBank: Mitotane (DB00648)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02003664
Drug: Baclofen ER
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
Study: NCT01485991
Drug: TVR
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Study: NCT03648905
Drug: 13N-Ammonia
Normalized name: (13N)Ammonia
DrugBank: Ammonia (DB11118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a perfusion imaging agent
Study: NCT03648905
Drug: 18F-DOPA
Normalized name: (-)-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: is a positron-emitting analog of the catechol amino acid, levodopa
Study: NCT03648905
Drug: 11C-Methylreboxetine (11C-MRB)
Normalized name: 11C-choline
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
Study: NCT00415883
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03047278
Drug: Gabapentin 300 mg
Normalized name: gabapentin 300 MG
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients were treated with oral single dose of gabapentin 300 mg.
Study: NCT03047278
Drug: Cetirizine Hydrochloride 10 mg
Normalized name: cetirizine hydrochloride 10 MG
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
Study: NCT02131155
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily
Study: NCT01675050
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 weeks of cyproheptadine or placebo with crossover to the other
Study: NCT01675050
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of cyproheptadine or placebo with crossover to the other
Study: NCT00452985
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-75 mg/m²
Study: NCT00452985
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5
Study: NCT04171258
Drug: Botulinum toxin type A injection
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Experimental
Study: NCT04171258
Drug: Botulinum Toxin Type A Injection [Botox]
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Active Comparator
Study: NCT02025985
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.
Study: NCT00386997
Drug: liposomal amphotericin B (AmBisome®)
Normalized name: amphotericin B liposomal Injection [AmBisome]
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03412513
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
Study: NCT02527863
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg Tolvaptan pr day for 1 day
Study: NCT00216788
Drug: Esomeprazole (Nexium) 40 mg/day
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00730392
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
Study: NCT03945773
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablets of 60mg, 40mg and 20 mg.
Study: NCT03575572
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
Study: NCT02328209
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
Study: NCT00221156
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03604653
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 30mg@ T0, 10mg@T45 min
Study: NCT03604653
Drug: CDDP 50
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2@T0
Study: NCT03604653
Drug: CDDP 75
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2@T0
Study: NCT03203473
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
Study: NCT03203473
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
Study: NCT03048058
Drug: brimonidine topical gel 0.33% & survey
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
Study: NCT03048058
Drug: brimonidine topical gel 0.33% & SOC
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive standard-of-care brimonidine topical gel 0.33%
Study: NCT03190330
Drug: Ibrutinib 420 mg
Normalized name: ibrutinib 420 MG
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
Study: NCT03190330
Drug: Ibrutinib 560 mg
Normalized name: ibrutinib 560 MG
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
Study: NCT03663543
Drug: Conjugated Estrogen
Normalized name: Conjugated estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Study: NCT03093116
Drug: Oral repotrectinib (TPX-0005)
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repotrectinib (TPX-0005) capsules.
Study: NCT00240097
Drug: Intervention A: Irinotecan; Oxaliplatin; Neulasta
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
Study: NCT00424177
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: experimental
Study: NCT00433498
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study: NCT00433498
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study: NCT00433498
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study: NCT04284774
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or via nasogastric or gastric tube
Study: NCT01178281
Drug: Pomalidomide 0.5 mg
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
Study: NCT01178281
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily.
Study: NCT02646189
Drug: Zadaxin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
Study: NCT02646189
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
Study: NCT00695370
Drug: Pegfilgrastim (drug)
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02977780
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temzolomide capsules
Study: NCT02977780
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib tablets
Study: NCT02160678
Drug: Tazarotene Cream, 0.1 %
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
Study: NCT00626158
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
Study: NCT01588171
Drug: Bemiparin
Normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
Study: NCT01588171
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
Study: NCT02706834
Drug: TAK-828
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-828 oral solution
Study: NCT03362047
Drug: Macitentan Group
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be administered 12 weeks Macitentan
Study: NCT03398434
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 5 mg b.i.d
Study: NCT01363544
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
Study: NCT04589390
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment with selexipag
Study: NCT02223507
Drug: BIIR 561 CL
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255515
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00609245
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
Study: NCT00825643
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
Study: NCT00218075
Drug: Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00829647
Drug: dasatinib and lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
Study: NCT01095601
Drug: Avanafil
Normalized name: Avanafil
DrugBank: Avanafil (DB06237)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted
Study: NCT02068352
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA-15406 1%-matching placebo topical ointment
Study: NCT00119314
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00119314
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03986944
Drug: 75 mg linzagolix tablet
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03986944
Drug: 200 mg linzagolix tablet
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03986944
Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03986944
Drug: Placebo tablet to match 75 mg linzagolix tablet
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03986944
Drug: Placebo tablet to match 200 mg linzagolix tablet
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT01233492
Drug: mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05087797
Drug: nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
Study: NCT01367613
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01145859
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
Study: NCT03327051
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) that suppresses gastric acid secretion
Study: NCT01399684
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study: NCT01399684
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
Study: NCT01399684
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study: NCT01399684
Drug: MEGF0444A
Normalized name: MEGF0444A
DrugBank: Parsatuzumab (DB14897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
Study: NCT01399684
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.